Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of patients previously exposed to UCART19
jRCT2013190001Active, not recruiting
- Sponsor
- Nihon Servier
- Start
- Mar 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Open-label, single-arm trial of UCART19 in lymphoma, acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by Nihon Servier. Primary endpoint: Long-term safety of UCART19. Started Mar 2020; status: active, not recruiting.
02
Drugs
UCART19
03
Conditions
lymphomaacute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2013190001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013190001.